Stay updated on Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page.

Latest updates to the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedNew revision entry v3.5.0 was added to the record history. Revision v3.4.3 was removed.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision: v3.4.3 was added to the history as the latest entry, replacing the previous v3.4.2.SummaryDifference0.1%

- Check44 days agoChange DetectedThe study title now specifies Etentamig (ABBV-383) for intravenous use in adults with relapsed or refractory multiple myeloma, with related sections added or updated accordingly.SummaryDifference0.6%

- Check51 days agoChange DetectedNew entry 'Revision: v3.4.2' was added to the record history. A general government operating status notice was removed from deletions.SummaryDifference0.4%

- Check58 days agoChange DetectedThe page history shows a site-wide notice about a lapse in government funding and operation status, and an update from Revision: v3.4.0 to v3.4.1; no substantive changes to the study record content were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check65 days agoChange DetectedThe history page now uses color-coded highlights to differentiate additions and deletions and includes a revision notice (v3.4.0). A glossary toggle to show glossary terms has been added.SummaryDifference0.6%

Stay in the know with updates to Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page.